Regulatory approval

Published by the Health Canada. Approved

BESPONSA (inotuzumab ozogamicin for injection) is indicated for monotherapy for the treatment of adults with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL).

This is written in the approval document.

Citation

Pfizer Canada ULC. Besponsa (inotuzumab ozogamicin) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00077730.PDF. Revised November 2024. Accessed June 2025.

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations	Biomarkers	Cancer types	Therapies
HC (1)	CD22 +	Acute Lymphoblastic Leukemia	Inotuzumab ozogamicin

Contributions

Date	Contributor	Description
2024-10-30	Van Allen lab	Initial access of FDA approvals